{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:16:33Z","timestamp":1773051393058,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007065","name":"Universit\u00e0 degli Studi di Salerno","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Due to the variety of clinical phenotypes and the massive clinical overlap with other neurodegenerative diseases, the diagnosis of Progressive Supranuclear Palsy (PSP) remains a major challenge. Notwithstanding, early and reliable clinical diagnosis of PSP is highly warranted for estimation of prognosis, appropriate allocation to therapeutic trials and development of new diagnostic tools. As reliable biomarkers are lacking, PSP diagnosis relies on the application of the clinical criteria promoted by the International Parkinson and Movement Disorder Society (MDS). Despite providing a framework including all the main PSP cornerstones (ocular dysfunction and postural instability, akinesia and cognitive dysfunction), the application of the MDS PSP criteria is complex and not straightforward to apply in a clinical setting. Herein we propose a practical tool, including a video-guided slide-set and a smartsheet, to disseminate the MDS PSP clinical criteria among healthy practitioners and increase confidence in non expert clinicians towards suspicion and diagnosis of PSP. The video-guided slide set may serve as a teaching resource for both general neurologists and practitioners, while the smartsheet may represent a valid support in attributing the degree of diagnostic certainty and phenotype based on the identified clinical features. Application of our tool may improve early recognition of patients in primary and secondary care and determine a prompt referral to third level movement disorder centers for consideration in clinical trials testing disease-modifying treatments.<\/jats:p>","DOI":"10.1007\/s10072-025-07996-0","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T01:21:36Z","timestamp":1736558496000},"page":"1959-1964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A smart tool for non expert clinicians for the dissemination of the MDS criteria for progressive supranuclear palsy"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9025-137X","authenticated-orcid":false,"given":"Marina","family":"Picillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Abate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Canoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Francesca","family":"Tepedino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Erro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"7996_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M, for the Movement Disorder Society\u2013endorsed PSP Study Group et al (2017) Clinical diagnosis of Progressive Supranuclear Palsy: the Movement Disorder Society Criteria. Mov Disord 32:853\u2013864","journal-title":"Mov Disord"},{"key":"7996_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00005072-199601000-00010","volume":"55","author":"I Litvan","year":"1996","unstructured":"Litvan I, Hauw JJ, Bartko JJ et al (1996) Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55:97\u2013105","journal-title":"J Neuropathol Exp Neurol"},{"key":"7996_CR3","doi-asserted-by":"crossref","unstructured":"Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1\u20139","DOI":"10.1212\/WNL.47.1.1"},{"key":"7996_CR4","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/mds.27666","volume":"34","author":"MJ Grimm","year":"2019","unstructured":"Grimm MJ, Respondek G, Stamelou M et al (2019) How to apply the Movement Disorder Society Criteria for Diagnosis of Progressive Supranuclear Palsy. Mov Disord 34:1228\u20131232","journal-title":"Mov Disord"},{"issue":"8","key":"7996_CR5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/mds.27408","volume":"33","author":"M Picillo","year":"2018","unstructured":"Picillo M, Erro R, Cuoco S, Tepedino MF, Manara R, Pellecchia MT, Barone P, PSP Salerno Study Group (2018) MDS PSP criteria in real-life clinical setting: motor and cognitive characterization of subtypes. Mov Disord 33(8):1361\u20131365","journal-title":"Mov Disord"},{"issue":"7","key":"7996_CR6","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00415-019-09324-x","volume":"266","author":"M Picillo","year":"2019","unstructured":"Picillo M, Cuoco S, Tepedino MF, Cappiello A, Volpe G, Erro R, Santangelo G, Pellecchia MT, Barone P, PSP Salerno study group (2019) Motor, cognitive and behavioral differences in MDS PSP phenotypes. J Neurol 266(7):1727\u20131735","journal-title":"J Neurol"},{"issue":"1","key":"7996_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz CG, Fahn S, Martinez-Martin P et al (2007) Movement Disorder Society\u2010Sponsored Revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS\u2010UPDRS): process, format, and clinimetric testing plan. Mov Disord 22(1):41\u201347","journal-title":"Mov Disord"},{"key":"7996_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"A Boxer","year":"2017","unstructured":"Boxer A, Yu JT, Golbe LI, Litvan I, Lang AE, H\u00f6glinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16:552\u2013563","journal-title":"Lancet Neurol"},{"issue":"1","key":"7996_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mds.27872","volume":"35","author":"G Respondek","year":"2020","unstructured":"Respondek G, Grimm MJ, Piot I et al (2020) Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord 35(1):171\u2013176","journal-title":"Mov Disord"},{"key":"7996_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2022.01.004","volume":"95","author":"D Street Duncan, Whiteside","year":"2022","unstructured":"Street Duncan, Whiteside D, Rittman T, Rowe JB (2022) Prodromal Progressive Supranuclear Palsy-insights from the UK Biobank. Parkinsonism Relat Disord 95:59\u201364","journal-title":"Parkinsonism Relat Disord"},{"key":"7996_CR11","doi-asserted-by":"publisher","first-page":"637176","DOI":"10.3389\/fneur.2021.637176","volume":"12","author":"MJ Kwasny","year":"2021","unstructured":"Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Hoglinger GU (2021) Clinical features observed in general practice associated with the susequent diagnosis of progressive supranuclear palsy. Front Neurol 12:637176","journal-title":"Front Neurol"},{"key":"7996_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.parkreldis.2020.03.003","volume":"74","author":"C Painous","year":"2020","unstructured":"Painous C, Mart\u00ed MJ, Simonet C, Garrido A, Valldeoriola F, Mu\u00f1oz E, C\u00e1mara A, Compta Y (2020) Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: the step-back PSP study. Parkinsonism Relat Disord 74:67\u201373","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"7996_CR13","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1002\/mds.28263","volume":"35","author":"MJ Grimm","year":"2020","unstructured":"Grimm MJ, Respondek G, Stamelou M, Arzberger T et al (2020) Clinical conditions suggestive of progressive supranuclear palsy-diagnostic performance. Mov Disord 35(12):2301\u20132313","journal-title":"Mov Disord"},{"issue":"2","key":"7996_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","volume":"77","author":"RM Tsai","year":"2020","unstructured":"Tsai RM, Miller Z, Koestler M et al (2020) Reactions to multiple ascending doses of the Microtubule stabilizer TPI-287 in patients with Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: a Randomized Clinical Trial. JAMA Neurol 77(2):215\u2013224","journal-title":"JAMA Neurol"},{"key":"7996_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.parkreldis.2020.06.030","volume":"78","author":"V Iankova","year":"2020","unstructured":"Iankova V, Respondek G, Saranza G et al (2020) Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. Parkinsonism Relat Disorders 78:200\u2013203","journal-title":"Parkinsonism Relat Disorders"},{"key":"7996_CR16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.410400630","volume":"40","author":"N Quinn","year":"1996","unstructured":"Quinn N (1996) The round the houses sign in progressive supranuclear palsy. Ann Neurol 40:951","journal-title":"Ann Neurol"},{"key":"7996_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.parkreldis.2020.08.014","volume":"79","author":"F Abate","year":"2020","unstructured":"Abate F, Picillo M, Della Rocca G, Barone P, Erro R (2020) The zig-zag sign in Progressive Supranuclear Palsy. Parkinsonism Relat Disord 79:86\u201387","journal-title":"Parkinsonism Relat Disord"},{"key":"7996_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.parkreldis.2020.10.030","volume":"81","author":"C Fearon","year":"2020","unstructured":"Fearon C, Field R, Donlon E et al (2020) The round the houses sign and zig-zag sign in progressive supranuclear palsy and other conditions. Parkinsonism Relat Disord 81:94\u201395","journal-title":"Parkinsonism Relat Disord"},{"key":"7996_CR19","doi-asserted-by":"crossref","unstructured":"Romano S, Colosimo C (2001) Procerus sign in progressive supranuclear palsy. 57(10):1928","DOI":"10.1212\/WNL.57.10.1928"},{"key":"7996_CR20","doi-asserted-by":"publisher","first-page":"117108","DOI":"10.1016\/j.jns.2020.117108","volume":"418","author":"L Marsili","year":"2020","unstructured":"Marsili L, Colosimo C (2020) The gunslinger sign in progressive supranuclear palsy - Richardson variant. J Neurol Sci 418:117108","journal-title":"J Neurol Sci"},{"key":"7996_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2463\/mrms.3.125","volume":"3","author":"M Adachi","year":"2004","unstructured":"Adachi M, Kawanami T, Ohshima H et al (2004) Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci 3:125\u2013132","journal-title":"Magn Reson Med Sci"},{"key":"7996_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1212\/01.wnl.0000203342.77115.bf","volume":"66","author":"K Gr\u00f6schel","year":"2006","unstructured":"Gr\u00f6schel K, Kastrup A, Litvan I et al (2006) Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology 66:949\u2013950","journal-title":"Neurology"},{"key":"7996_CR23","doi-asserted-by":"crossref","unstructured":"Picillo M, Tepedino MF, Abate F et al (2020) Midbrain MRI assessments in progressive supranuclear palsy subtypes. 2020, Journal of Neurology, Neurosurgery and Psychiatry 91:98\u2013103","DOI":"10.1136\/jnnp-2019-321354"},{"key":"7996_CR24","first-page":"7","volume":"7","author":"AM Vlaar","year":"2001","unstructured":"Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE (2001) Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 7:7\u201327","journal-title":"BMC Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-07996-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-07996-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-07996-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:57:02Z","timestamp":1744804622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-07996-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7996"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-07996-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"25 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to add the missing ESM file.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present work does not require approval from Ethical Committee. Patients videotaped signed a written informed consent authorizing publication and use for educational purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None declared. Disclosures from the past two years: Dr Marina Picillo is supported by the Michael J Fox Foundation for Parkinson's research; Prof Paolo Barone received consultancies as a member of the advisory board for Zambon, Lundbeck, UCB, Chiesi, Abbvie and Acorda; the other authors report no financial diclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}